📰 Full Story
U.S. health authorities are tracking a heavily mutated SARS‑CoV‑2 subvariant, BA.3.2 (nicknamed “Cicada”), after detections in traveler, clinical and wastewater samples.
First identified in South Africa in November 2024, the lineage was picked up in the United States by traveller‑based surveillance in June 2025 and, according to a CDC report covering data through Feb. 11, 2026, has been found in at least 23 countries and in wastewater or clinical samples from roughly two dozen U.S. states.
BA.3.2 carries an estimated 70–75 spike‑protein substitutions and deletions relative to recently circulating strains, laboratory analyses indicate moderate immune‑escape properties, and some studies show reduced neutralisation by the 2025–26 LP.8.1‑adapted mRNA vaccine.
So far the variant remains a small fraction of sequenced U.S. cases and has not been clearly linked to higher hospitalisation or death rates, but it accounted for up to about 30% of sequenced cases in parts of northern Europe between November 2025 and January 2026.
The CDC and WHO have designated BA.3.2 for close monitoring and emphasise continued genomic and wastewater surveillance, vaccination and targeted public‑health vigilance.
🔗 Based On
International Business TimesCOVID-19 BA.3.2 Variant First Detected In SFO Traveller: Experts Warn On Symptoms, Spread And Hidden Surge Risk
Morning OverviewCDC flags BA.3.2 COVID variant after dozens of U.S. detections






💬 Commentary